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The recent discovery of a xenotropic murine leukemia virus-
related retrovirus (designated as XMRV) in prostate cancer
tissues and later in chronic fatigue syndrome (CFS) patients
created excitement related to possible association of a virus
withthesehumandiseases.However,thefailuretoreproduce
such results in other laboratories raised concerns and much
debate among scientists, patient populations, and clinicians
over the original ﬁndings. This special issue is a collection of
recent research reports, that address this controversy. It also
includes several expert reviews on various aspects of murine
retroviruses, such as virus biology, replication, phylogeny,
and pathogenesis, as well as XMRV in prostate cancer.
The ﬁrst paper by A. Rein reviews the murine retrovirus
genomic structure, viral structural proteins, and virus repli-
cation. The second p a p e rb yC .A .K o z a kp r o v i d e sad e t a i l e d
review of murine retrovirus entry into the cell and diﬀerent
receptor usage by diﬀerent types of murine retroviruses with
comparison to XMRV. The third paper by J. Blomberg et
al. discusses the phylogenetic analysis of murine retroviruses
and other retroviruses. The fourth paper by J. Chakraborty
et al. discusses murine retrovirus pathogenesis and a mouse
model for transmission of lymphoma by breast milk. The
ﬁfthpaperb yD .E.K angetal.reviewsthediscovery,progress,
and current status of XMRV ﬁndings in prostate cancer
patients. The sixth paper by S. Tang and I. K. Hewlett
reviewsXMRVdetectionassaysanddeﬁcienciesinthetesting
methods. The seventh paper by J. M. Coﬃn and O. Cing¨ oz
provides a detailed review of the controversies related to the
XMRV results in human clinical samples and the ﬁndings
regarding virus origin and discusses the potential sources of
contamination that resulted in the misidentiﬁcation of the
v i r u sa san o v e lh u m a nr e t r o v i r u s .
Additionally, the special issue contains various research
papers demonstrating the absence of XMRV in various
patient populations using sensitive assays for virus detection.
The eighth paper by B. Oakes et al. reports the absence of
antibodies in CFS patients and healthy controls using two
novel sensitive immunoassays. Theninth paper by J. Spindler
et al. reports the lack of evidence of XMRV infection in HIV-
1 infected men or men at high risk for HIV-1 infection by
analyzing PBMCs and plasma samples using sensitive PCR
assays and immunoassays. The tenth paper by K. A. Delviks-
Frankenberry et al. demonstrates the absence of XMRV in
PBMCs and plasma from HIV-1 lymphoma patients using
PCRorimmunoassays.TheeleventhpaperbyM.J.Robinson
et al. indicates the absence of XMRV sequences in prostate
cancer samples from diverse populations, B-cell lymphoma
patients, as well as UK blood donors. The twelfth paper by
M. Kearney et al. reports the use of diﬀerent methodologies
to demonstrate the absence of XMRV in plasma and in
some tissue samples from prostate cancer patients. The ﬁnal,
thirteenthpaperbyP .Sharmaetal.describesXMRVinfection2 Advances in Virology
in the reproductive tissues of rhesus monkeys, proposing the
possibility of an animal model for further investigations of
virus transmission.
This special issue provides the recent thinking and
research results of studies on XMRV and other murine
leukemiaretrovirus-relatedsequencesinhumans.Numerous
studies have failed to conﬁrm the presence of XMRV in
humans, and XMRV has recently been found to be a
laboratory-derived rare recombinant, which originated by
xenografting a patient’s prostate cancer cells in nude mice.
A consensus has now emerged that XMRV footprints or
infectious XMRV detected in normal human individuals or
in some diseased patients represents laboratory contamina-
tions. The information provided in this issue should be of
interest to a broad audience including scientists, clinicians,
patient populations, and public health agencies.
Arifa S. Khan
Myra McClure
Yoshinao Kubo
Paul Jolicoeur